GO
Loading...

Enter multiple symbols separated by commas

Stocks Abbott Laboratories

More

  • Abbott Labs makes 2 heart valve replacement deals Thursday, 30 Jul 2015 | 3:04 PM ET

    NEW YORK— Medical device maker Abbott Laboratories said Thursday it has agreed to buy replacement heart valve maker Tendyne Holdings for $225 million, and has invested in a second company in the field. Tendyne is conducting a U.S. clinical trial of a product called the bioprosthetic mitral valve system and it plans to start a study in 2016 to support approval of...

  • Abbott beats Street 2Q forecasts Wednesday, 22 Jul 2015 | 7:51 AM ET

    NORTH CHICAGO, Ill.— Abbott Laboratories on Wednesday reported second-quarter net income of $784 million. The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of 50 cents per share. Ten analysts surveyed by Zacks expected $5.16 billion.

  • MUMBAI, July 16- India has extended price caps to an additional 39 drugs ranging from commonly used diabetes treatments to antibiotics, in the government's latest effort to improve the affordability of medicines. Wide-ranging price cuts over the past year have hit several drugmakers in India and have been opposed by many in the industry, who say drug prices in...

  • Two big problems with generic-drug substitution Tuesday, 23 Jun 2015 | 3:54 PM ET
    Pharmaceutical drugs

    Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.

  • TEL AVIV, June 23- Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said. Mylan has offered to acquire Perrigo for $34 billion in an attempt to fend off a bid from Israel's Teva...

  • June 16- Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend of interest from Teva Pharmaceutical Industries Ltd. Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's "standalone strategy" and believed acquiring Perrigo...

  • Abbott to vote for Mylan's acquisition of Perrigo Tuesday, 16 Jun 2015 | 9:20 AM ET

    June 16- Abbott Laboratories said it would vote its 14.5 percent stake in Mylan NV in favor of Mylan's proposed acquisition of Perrigo Company Plc. Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs. Abbott, Mylan's largest shareholder, said...

  • Biotech isn't only health-care bet beating market Monday, 1 Jun 2015 | 10:09 AM ET
    An employee works on a stent graft component in a sterile environment at the Medtronic assembly plant in Tijuana, Mexico.

    The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.

  • Value investor: Bet on an eBay dividend Wednesday, 20 May 2015 | 7:28 AM ET

    Susan Byrne, founder and chairman of Westwood Holdings, is making a bet that eBay will likely issue a dividend following the spin off of PayPal.

  • A third of Pedialyte's sales now comes from adults Monday, 18 May 2015 | 7:24 PM ET
    Pedialyte a hangover cure? The company increases its focus on adult consumers.

    The drink once reserved for young kids has made new inroads with hungover adults.

  • Hungover? Pedialyte wants your business Wednesday, 13 May 2015 | 2:51 PM ET
    Pedialyte a hangover cure? The company increases its focus on adult consumers.

    Pedialyte is going after a new market, and they don't have a bedtime...

  • *Tie-up with Montreal scientists on heart disease genes. LONDON, May 13- AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease. To redress the balance, AstraZeneca said on Wednesday it had signed two deals, one with Abbott Laboratories for a diagnostic test...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co and believes it can complete the deal by year end. Mylan, on a conference call with analysts, said it is legally committed to take its offer directly to Perrigo shareholders under Irish takeover...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co.. "We remain steadfast in our legally binding commitment to acquire Perrigo and have taken numerous concrete steps to lay out a clear and certain path towards completion," Mylan Chief Executive...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland- based Perrigo Co.. Perrigo last week rejected a sweetened $34 billion offer from Mylan. At the same time, Mylan is attempting to fend...

  • April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.

  • April 22- Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million, or 14 cents per share, a year earlier.

  • April 22- Abbott Laboratories' net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million,...

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.